Final Results | 14-May-2024 | 07:00 | RNS |
Fundraise, RCF Extension, Termination of CLN & TVR | 10-May-2024 | 07:00 | RNS |
Product Supplied to First Two Sales Contracts | 14-Dec-2023 | 07:00 | RNS |
Fundraise, Update on Future CLN Financing & TVR | 12-Dec-2023 | 14:00 | RNS |
New European Sales Contract | 16-Nov-2023 | 07:00 | RNS |
Fundraise, CLN Issue, Joint Broker Appointed & TVR | 13-Oct-2023 | 07:00 | RNS |
Interim Results | 28-Sep-2023 | 07:00 | RNS |
Notice of Results and Investor Presentation | 18-Sep-2023 | 07:00 | RNS |
New Sales Contract with UK Pharmaceutical Company | 05-Sep-2023 | 07:00 | RNS |
Approval to roll-out chronic pain clinical trial | 01-Aug-2023 | 07:00 | RNS |
Result of AGM | 29-Jun-2023 | 17:30 | RNS |
Publication of Annual Report and Notice of AGM | 05-Jun-2023 | 14:46 | RNS |
Final Results for the year ended 31 December 2022 | 05-Jun-2023 | 07:00 | RNS |
£7 Million Committed Credit Facility | 30-May-2023 | 07:00 | RNS |
Notice of Results and Investor Presentation | 26-May-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 104.29p |
Change Today | 1.79p |
% Change | 1.74 % |
52 Week High | 172.50 |
52 Week Low | 79.00 |
Volume | 100 |
Shares Issued | 64.21m |
Market Cap | £66.96m |
RiskGrade | 111 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
10:04 | 100 @ 100.00p |
CEO | James Short |
CFO | Jonathan Turner |
You are here: research